Rallybio Statistics
Total Valuation
Rallybio has a market cap or net worth of $90.86 million. The enterprise value is -$1.99 million.
| Market Cap | 90.86M |
| Enterprise Value | -1.99M |
Important Dates
The next estimated earnings date is Thursday, November 5, 2026, before market open.
| Earnings Date | Nov 5, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Rallybio has 5.31 million shares outstanding. The number of shares has increased by 2.02% in one year.
| Current Share Class | 5.31M |
| Shares Outstanding | 5.31M |
| Shares Change (YoY) | +2.02% |
| Shares Change (QoQ) | +1.92% |
| Owned by Insiders (%) | 19.21% |
| Owned by Institutions (%) | 38.50% |
| Float | 1.75M |
Valuation Ratios
The trailing PE ratio is 2.14.
| PE Ratio | 2.14 |
| Forward PE | n/a |
| PS Ratio | 140.41 |
| Forward PS | n/a |
| PB Ratio | 0.96 |
| P/TBV Ratio | 0.96 |
| P/FCF Ratio | 3.40 |
| P/OCF Ratio | 3.40 |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 27.26
| Current Ratio | 27.26 |
| Quick Ratio | 26.03 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is 64.86% and return on invested capital (ROIC) is -935.26%.
| Return on Equity (ROE) | 64.86% |
| Return on Assets (ROA) | -21.32% |
| Return on Invested Capital (ROIC) | -935.26% |
| Return on Capital Employed (ROCE) | -26.90% |
| Weighted Average Cost of Capital (WACC) | 0.32% |
| Revenue Per Employee | $92,286 |
| Profits Per Employee | $6.51M |
| Employee Count | 7 |
| Asset Turnover | 0.01 |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, Rallybio has paid $1.32 million in taxes.
| Income Tax | 1.32M |
| Effective Tax Rate | 2.82% |
Stock Price Statistics
The stock price has increased by +312.19% in the last 52 weeks. The beta is -0.71, so Rallybio's price volatility has been lower than the market average.
| Beta (5Y) | -0.71 |
| 52-Week Price Change | +312.19% |
| 50-Day Moving Average | 16.70 |
| 200-Day Moving Average | 11.86 |
| Relative Strength Index (RSI) | 54.00 |
| Average Volume (20 Days) | 9,838 |
Short Selling Information
The latest short interest is 55,556, so 1.05% of the outstanding shares have been sold short.
| Short Interest | 55,556 |
| Short Previous Month | 54,943 |
| Short % of Shares Out | 1.05% |
| Short % of Float | 3.18% |
| Short Ratio (days to cover) | 5.21 |
Income Statement
In the last 12 months, Rallybio had revenue of $646,000 and earned $45.55 million in profits. Earnings per share was $7.99.
| Revenue | 646,000 |
| Gross Profit | -9.18M |
| Operating Income | -25.42M |
| Pretax Income | 46.88M |
| Net Income | 45.55M |
| EBITDA | -25.38M |
| EBIT | -25.42M |
| Earnings Per Share (EPS) | $7.99 |
Balance Sheet
The company has $92.85 million in cash and no debt, with a net cash position of $92.85 million or $17.48 per share.
| Cash & Cash Equivalents | 92.85M |
| Total Debt | n/a |
| Net Cash | 92.85M |
| Net Cash Per Share | $17.48 |
| Equity (Book Value) | 94.50M |
| Book Value Per Share | 17.81 |
| Working Capital | 93.69M |
Cash Flow
| Operating Cash Flow | 26.71M |
| Capital Expenditures | n/a |
| Depreciation & Amortization | 43,000 |
| Net Borrowing | n/a |
| Free Cash Flow | 26.71M |
| FCF Per Share | $5.03 |
Margins
| Gross Margin | n/a |
| Operating Margin | -3,935.45% |
| Pretax Margin | 7,256.19% |
| Profit Margin | 7,051.24% |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | 4,134.98% |
Dividends & Yields
Rallybio does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -2.02% |
| Shareholder Yield | -2.02% |
| Earnings Yield | 50.22% |
| FCF Yield | 29.45% |
Analyst Forecast
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on February 6, 2026. It was a reverse split with a ratio of 1:8.
| Last Split Date | Feb 6, 2026 |
| Split Type | Reverse |
| Split Ratio | 1:8 |
Scores
Rallybio has an Altman Z-Score of 2.9 and a Piotroski F-Score of 4. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 2.9 |
| Piotroski F-Score | 4 |